The China’s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical Co., Ltd’s (SHA: 688506) BL-M08D1 and CSPC Pharmaceutical Group Ltd’s (HKG: 1093) SYS6010 are on track to obtain Breakthrough Therapy Designations (BTDs) from the agency. These designations are for the treatment of recurrent small cell lung cancer patients who have failed previous platinum-based chemotherapy and anti-PD-1/PD-L1 monoclonal antibody treatment, and EGFR mutant advanced non-small cell lung cancer (NSCLC) that has failed treatment with EGFR-TKI and platinum-based chemotherapy, respectively.
BL-M08D1: An Innovative ADC Targeting EGFR and HER3
BL-M08D1, an in-house developed antibody drug conjugate (ADC) targeting EGFR and HER3, was out-licensed to US major Bristol-Myers Squibb (BMS; NYSE: BMY) at the end of 2023 in a deal worth USD 8.4 billion. This drug has previously obtained four BTD statuses in China, involving NSCLC, nasopharyngeal carcinoma, and esophageal squamous cell carcinoma, highlighting its potential impact on various cancer treatments.
SYS6010: A Promising ADC with Global Patent Protection
SYS6010 is also an ADC product that has demonstrated good anti-tumor activities in multiple cancers in pre-clinical studies. The drug has been filed for patent protection both domestically and internationally, indicating the company’s commitment to securing intellectual property rights and expanding its global reach.-Fineline Info & Tech
